|
|
Article: FDA Approves Biex Test to Aid in Identifying Risk of Preterm Labor and Delivery.
- Article from:
- Business Wire
- Article date:
- May 5, 1998
CopyrightCOPYRIGHT 1998 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Calif.--(BW HealthWire)--May 5, 1998--Biex, Inc. announced today the FDA granted marketing approval for the Company's salivary estriol test to help physicians identify risk for spontaneous preterm labor and delivery.
The SalEst(TM) system is approved for use in women between their 22nd and 36th week of pregnancy.
The proprietary SalEst system measures levels of the hormone, estriol, in saliva. Clinical research demonstrates that there is a surge in salivary estriol several weeks prior to the onset of spontaneous preterm labor and that salivary estriol testing is more accurate in predicting risk than traditional risk scoring methods. ...